Precision biosciences inc stock.

Nov 30, 2023 · The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […] Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Precision BioSciences Inc share price live 0.4366, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precision BioSciences Inc real time stock price chart below ...

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023 ... Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select …

November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...

Nov 30, 2023 · The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […] About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life ... risks related to ownership of our common stock; ...DTIL | Complete Precision Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.The short interest in Precision Biosciences Inc (NASDAQ:DTIL) is 0.85 million shares and it means that shorts have 0.83 day (s) to cover. The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 86.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 ...

Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.

Precision BioSciences, Inc. | 18,265 followers on LinkedIn. Dedicated to Improving Life. | Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo ...

Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), …DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish …WebPrecision BioSciences Inc stock price live 0.2969, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote.Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) Simply Wall St. August 6, 2023 at 5:03 AM · 2 min read. Celebrations may be in order for Precision ...WebDURHAM, N.C.--(BUSINESS WIRE)--Nov. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.Precision BioSciences, Inc. (DTIL) Stock Price, Quote, News & Analysis DTIL Precision BioSciences, Inc. Stock Price & Overview $0.37 0.0099 ( +2.79%) 3:59 …

Medicure Inc has a Value Score of 85, which is considered to be undervalued. Medicure Inc’s price-earnings ratio is 7.5 compared to the industry median at 21.6. This means that it has a lower price relative to its earnings compared to its peers. This makes Medicure Inc more attractive for value investors.Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones.Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress. October 12, 2023 Investor RSS News. DURHAM, N.C. --(BUSINESS WIRE)--Oct. 12, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to …WebNovember 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...We note from Precision Biosciences Inc’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.15 million. Precision Biosciences Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.50.

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company's advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT …

Real time Precision BioSciences (DTIL) stock price quote, stock graph, ... Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies ...WebWhat are individual investors saying about Precision BioSciences? View the latest DTIL social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the …WebJun 20, 2023 · Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,897,221 shares. Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish …WebCAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases ...November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...

This free interactive report on Precision BioSciences' balance sheet strength is a great place to start, if you want to investigate the stock further. A Different Perspective. Given that the market gained 5.6% in the last year, Precision BioSciences shareholders might be miffed that they lost 65%.

June 23, 2022 at 12:08 PM · 3 min read. Shares of Precision BioSciences, Inc. DTIL have remained up so far this week as the company has entered into an exclusive worldwide in vivo gene-editing ...

Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions. Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is ...The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. …DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...Expanded Access. Precision BioSciences is currently investigating multiple off-the-shelf allogeneic CAR T cell therapy candidates as potential treatment options for patients with hematologic blood cancers. Precision does not currently offer patients Expanded Access to investigational therapies outside of clinical trials. We believe that ...WebDURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings PreviewDURHAM, N.C.--(BUSINESS WIRE)--May 31, 2023-- Precision BioSciences, Inc. ... risks related to ownership of our common stock, including fluctuations in our stock price, and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, ...Web

Nov 7, 2023 · November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,... View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ.Dec 1, 2023 · About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. Instagram:https://instagram. how much is 1 bar of gold worthaverage dividend yield sandp 500what bank gives you a debit card the same daydripcees What are individual investors saying about Precision BioSciences? View the latest DTIL social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the …Web online banks with digital debit cardsvdadx dividend yield Operating Status Active; Last Funding Type Post-IPO Equity; Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL; Company Type For Profit. Contact ...Dec 21, 2021 · DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ... et stock price target November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.